Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19
- PMID: 33190086
- PMCID: PMC7648522
- DOI: 10.1016/j.rmed.2020.106188
Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19
Abstract
Objectives: Cytokine release syndrome (CRS) is a potentially severe complication of COVID-19 most commonly resulting in respiratory failure. This ten-patient study was designed to determine the efficacy of therapeutic plasma exchange (TPE) in improving oxygenation and in reducing the cytokine load in a critically ill subset of patients.
Methods: Five single volume plasma exchanges over eight days within a 14-day study period. In mechanically ventilated patients, oxygenation was measured via the PaO2/FiO2 (P/F) ratio and the oxygenation index (OI) daily for 14 days. Supplemental oxygen requirements were tracked daily for non-ventilated patients.
Results: Non-ventilated patients were liberated from supplemental oxygen after TPE. The response was rapid with an 87% average reduction in oxygenation requirements following and average time to return to room air of 5.25 days. All mechanically ventilated patients demonstrated improvement in oxygenation with a 78% average improvement in the P/F ratio and a 43% improvement in OI. C-reactive protein (CRP) and serum levels of IL-6, IL-8, IL-10, TNFα, IFNγ and GM-CSF, were measured daily with immediate post TPE levels drawn on days 1, 2, 4, 6 and 8. All patients demonstrated significant reductions in CRP, IL-6, IL-10 and TNFα.
Conclusions: In the majority of patients with Penn class 3 and 4 CRS complicating COVID-19, TPE demonstrated a prompt improvement in oxygenation and reduction in cytokine load without compromising patient safety. As this pilot study was envisioned to be hypothesis generating, expanded trials using TPE alone and in conjunction with novel pharmacologic agents are warranted.
Registration: ClinicalTrials.gov NCT04374149.
Keywords: COVID-19; Cytokine release syndrome; Oxygenation; Respiratory failure; Therapeutic benefit; Therapeutic plasma exchange.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: W. Jeffery Edenfield serves as a consultant for Chimerix, Inc., unrelated to the submitted work. The remaining authors have disclosed that they do not have any conflicts of interest.
Figures

Similar articles
-
Therapeutic plasma exchange in the treatment of COVID-19 induced cytokine storm: the first Moroccan experience.BMC Infect Dis. 2023 Nov 25;23(1):829. doi: 10.1186/s12879-023-08816-6. BMC Infect Dis. 2023. PMID: 38007416 Free PMC article.
-
Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study.J Crit Care. 2020 Dec;60:328-333. doi: 10.1016/j.jcrc.2020.07.001. Epub 2020 Jul 31. J Crit Care. 2020. PMID: 32763058 Free PMC article.
-
Therapeutic plasma exchange in a critically ill Covid-19 patient.J Clin Apher. 2021 Feb;36(1):179-182. doi: 10.1002/jca.21830. Epub 2020 Sep 1. J Clin Apher. 2021. PMID: 32875601
-
Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndrome.Transfus Apher Sci. 2022 Aug;61(4):103433. doi: 10.1016/j.transci.2022.103433. Epub 2022 Mar 23. Transfus Apher Sci. 2022. PMID: 35341691 Free PMC article. Review.
-
What Is the Role of Therapeutic Plasma Exchange as an Adjunctive Treatment in Severe COVID-19: A Systematic Review.Viruses. 2021 Jul 28;13(8):1484. doi: 10.3390/v13081484. Viruses. 2021. PMID: 34452349 Free PMC article.
Cited by
-
Cardiovascular Outcomes in Children with Multisystem Inflammatory Syndrome Treated with Therapeutic Plasma Exchange.Children (Basel). 2022 Oct 27;9(11):1640. doi: 10.3390/children9111640. Children (Basel). 2022. PMID: 36360368 Free PMC article.
-
The report from ASFA COVID-19 taskforce: Considerations and prioritization on apheresis procedures during the SARS-CoV-2 coronavirus disease (COVID-19) pandemic.J Clin Apher. 2021 Dec;36(6):878-881. doi: 10.1002/jca.21939. Epub 2021 Sep 12. J Clin Apher. 2021. PMID: 34510542 Free PMC article. Review.
-
Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.J Clin Immunol. 2021 Apr;41(3):536-544. doi: 10.1007/s10875-021-00994-9. Epub 2021 Feb 22. J Clin Immunol. 2021. PMID: 33616813 Free PMC article.
-
The Impact of Therapeutic Plasma Exchange on Inflammatory Markers and Acute Phase Reactants in Patients with Severe SARS-CoV-2 Infection.Medicina (Kaunas). 2023 Apr 29;59(5):867. doi: 10.3390/medicina59050867. Medicina (Kaunas). 2023. PMID: 37241099 Free PMC article. Review.
-
Use of therapeutic plasma exchange in COVID-19: A systematic review of current evidence.Ther Apher Dial. 2022 Dec;26 Suppl 1(Suppl 1):3-11. doi: 10.1111/1744-9987.13779. Epub 2022 Dec 5. Ther Apher Dial. 2022. PMID: 36468346 Free PMC article.
References
-
- Novel Coronavirus Situation Report-2. World Health Organization; Geneva: January 2020. https://www.who.int/docs/default-source/coronavirus/situation-reports/20...
-
- Transmission of SARS-CoV-2: Implications for Infection Prevention Precautions. World Health Organization; Geneva: July 2020. https://www.who.int/publications/i/item/modes-of-transmission-of-virus-c...
-
- Padmanabhan A., Connelly-Smith L., Aqui N., et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J. Chromatogr., A. 2019;34(3):167–354. - PubMed
-
- Busund R., Koukline V., Utrobin U., et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002;28:1434–1439. - PubMed
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous